Blood Test Found for Early Lung Cancer Detection

A collaborative research team has developed a groundbreaking blood-based biomarker that can detect early-stage lung cancer and forecast patient outcomes, according to a study published in the *Journal of Extracellular Vesicles*. The discovery, which leverages extracellular vesicles—tiny cell-derived particles circulating in blood—their findings offer a non-invasive alternative to traditional diagnostic methods, potentially improving early detection rates for the disease, which remains a leading cause of cancer-related deaths globally.

The biomarker identifies specific proteins and microRNAs within extracellular vesicles that correlate with lung cancer presence and progression. In clinical validation, the test demonstrated high accuracy in distinguishing early-stage tumors from benign conditions and healthy controls, using blood samples from over 300 participants. Researchers also found the biomarker’s molecular profile could predict survival outcomes, enabling stratification of patients into high- or low-risk groups. This dual functionality addresses critical gaps in lung cancer management, where early diagnosis and prognosis remain challenging due to the disease’s aggressive nature and nonspecific symptoms.

The study underscores the potential of extracellular vesicles as a versatile tool in precision oncology. If validated in larger trials, the biomarker could streamline screening for high-risk populations, reduce reliance on invasive biopsies, and inform personalized treatment strategies. The research team emphasizes the need for further clinical trials to assess scalability and cost-effectiveness, with the ultimate goal of integrating this test into routine medical practice to enhance lung cancer care.